VanEck Pharma ETF (NASDAQ:PPH – Get a rating) was the subject of unusual options trading on Monday. Stock traders bought 3,355 call options on the stock. This represents a 433% increase from the average daily volume of 630 call options.
Institutional investors weigh in on VanEck Pharmaceutical ETF
Several institutional investors and hedge funds have recently changed their PPH holdings. Altfest LJ & Co. Inc. increased its holdings in VanEck Pharmaceutical ETF by 72.7% in the first quarter. Altfest LJ & Co. Inc. now owns 89,416 shares of the company valued at $7,132,000 after purchasing an additional 37,634 shares in the last quarter. International Assets Investment Management LLC bought a new position in VanEck Pharmaceutical ETF in the first quarter worth approximately $279,000. Lansing Street Advisors bought a new position in VanEck Pharmaceutical ETF in the first quarter worth about $1,700,000. Qube Research & Technologies Ltd increased its holdings in VanEck Pharmaceutical ETF by 56.4% in the first quarter. Qube Research & Technologies Ltd now owns 638 shares in the company valued at $51,000 after buying an additional 230 shares in the last quarter. Finally, Phoenix Holdings Ltd. bought a new position in VanEck Pharmaceutical ETF in the first quarter worth approximately $7,094,000.
Pharmaceuticals ETF VanEck stock performance
NASDAQ:PPH traded at $0.92 on Monday, reaching $73.62. 5,847 shares were traded, against an average volume of 152,575. The stock has a fifty-day moving average of $70.14 and a 200-day moving average of $74.06. VanEck Pharmaceutical ETF has a fifty-two week low of $66.59 and a fifty-two week high of $84.27.
VanEck Pharmaceutical ETF increases its dividend
The company also recently announced a quarterly dividend, which was paid on Friday, October 7. Shareholders of record on Tuesday, October 4 received a dividend of $0.27. This is an increase from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.25. The ex-dividend date was Monday, October 3. This represents an annualized dividend of $1.08 and a dividend yield of 1.47%.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider the VanEck pharma ETF, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads…and that the VanEck Pharmaceutical ETF didn’t make the list.
While VanEck Pharmaceutical ETF currently has an “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.